Other OTC - Delayed Quote • USD
Q BioMed Inc. (QBIO)
As of May 10 at 9:46 AM EDT. Market Open.
Breakdown
TTM
11/30/2022
11/30/2021
11/30/2020
Total Revenue
209.2930
284.3520
195.5970
30.0000
Cost of Revenue
221.8950
293.3400
246.8460
326.0090
Gross Profit
-12.6020
-8.9880
-51.2490
-296.0090
Operating Expense
2,713.5680
3,436.6270
7,337.3160
12,849.4050
Operating Income
-2,726.1700
-3,445.6150
-7,388.5650
-13,145.4140
Net Non Operating Interest Income Expense
-1,247.0670
-1,384.4650
-506.9220
-296.2150
Other Income Expense
--
2,777.9880
-345.0630
-50.5620
Pretax Income
-485.4570
-2,052.0920
-8,240.5500
-13,492.1910
Net Income Common Stockholders
-1,909.0650
-3,494.0840
-8,741.2740
-14,350.2150
Diluted NI Available to Com Stockholders
-1,909.0650
-3,494.0840
-8,741.2740
-14,350.2150
Basic EPS
-0.02
-0.08
-0.33
-0.65
Diluted EPS
-0.02
-0.08
-0.33
-0.65
Basic Average Shares
64,540.6810
44,756.8180
26,779.2700
22,160.4260
Diluted Average Shares
64,540.6810
44,756.8180
26,779.2700
22,160.4260
Total Operating Income as Reported
-2,726.1720
-3,445.6160
-7,388.5650
-13,145.4140
Total Expenses
2,935.4630
3,729.9670
7,584.1620
13,175.4140
Net Income from Continuing & Discontinued Operation
-485.0820
-2,052.0930
-8,240.5500
-13,492.1910
Normalized Income
-587.7860
-1,686.8800
-7,895.4870
-13,441.6290
Interest Expense
1,247.0670
1,384.4650
506.9220
296.2150
Net Interest Income
-1,247.0670
-1,384.4650
-506.9220
-296.2150
EBIT
761.6100
-667.6270
-7,733.6280
-13,195.9760
EBITDA
811.6100
-617.6270
-7,683.6280
-13,145.9760
Reconciled Cost of Revenue
221.8950
293.3400
246.8460
326.0090
Reconciled Depreciation
50.0000
50.0000
50.0000
50.0000
Net Income from Continuing Operation Net Minority Interest
-485.0820
-2,052.0930
-8,240.5500
-13,492.1910
Total Unusual Items Excluding Goodwill
102.7040
-365.2130
-345.0630
-50.5620
Total Unusual Items
102.7040
-365.2130
-345.0630
-50.5620
Normalized EBITDA
708.9060
-252.4140
-7,338.5650
-13,095.4140
11/30/2020 - 6/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AXIM AXIM Biotechnologies, Inc.
0.0101
+1.00%
NBIO Nascent Biotech, Inc.
0.0995
0.00%
UP0.DU Ultragenyx Pharmaceutical Inc
38.00
+1.06%
RDTCF Rapid Dose Therapeutics Corp.
0.0151
0.00%
ORGS Orgenesis Inc.
0.6298
+3.25%
NAVB Navidea Biopharmaceuticals, Inc.
0.0300
-14.29%
OVIT OncoVista Innovative Therapies, Inc.
0.0001
0.00%
NTII Neurobiological Technologies, Inc.
0.0000
0.00%
PMCB PharmaCyte Biotech, Inc.
2.1900
+7.58%
PRED Predictive Technology Group, Inc.
0.0006
0.00%